Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26432056 | 0.79 | KDM4E (0.32) | ALDH1A1KDM4E | |
| SCHEMBL26262661 | 0.78 | KDM4E (0.33) | ALDH1A1KDM4EGRM5 | |
| SCHEMBL26422702 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL7167679 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL23385228 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL16644707 | 0.72 | GRM5 (0.38) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL26422705 | 0.72 | KDM4E (0.38) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL16632648 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL7170576 | 0.71 | ALDH1A1 (0.43) | ALDH1A1KDM4EGRM5NPC1NFKB1 | |
| SCHEMBL7169178 | 0.66 | TDP1 (0.44) | ALDH1A1KDM4ENPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | ALDH1A1 3447/4885KDM4E 133/4885GRM5 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.